267 related articles for article (PubMed ID: 11716838)
21. The pharmacology of sildenafil, a novel and selective inhibitor of phosphodiesterase (PDE) type 5.
Wallis RM
Nihon Yakurigaku Zasshi; 1999 Oct; 114 Suppl 1():22P-26P. PubMed ID: 10629850
[TBL] [Abstract][Full Text] [Related]
22. Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat.
Prickaerts J; van Staveren WC; Sik A; Markerink-van Ittersum M; Niewöhner U; van der Staay FJ; Blokland A; de Vente J
Neuroscience; 2002; 113(2):351-61. PubMed ID: 12127092
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of type-5 phosphodiesterase: promising therapy for pulmonary hypertension.
Watanabe H
Intern Med; 2004 Oct; 43(10):891-3. PubMed ID: 15575233
[No Abstract] [Full Text] [Related]
24. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.
Blount MA; Beasley A; Zoraghi R; Sekhar KR; Bessay EP; Francis SH; Corbin JD
Mol Pharmacol; 2004 Jul; 66(1):144-52. PubMed ID: 15213306
[TBL] [Abstract][Full Text] [Related]
25. High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients.
Weeks JL; Zoraghi R; Beasley A; Sekhar KR; Francis SH; Corbin JD
Int J Impot Res; 2005; 17(1):5-9. PubMed ID: 15538396
[TBL] [Abstract][Full Text] [Related]
26. Sildenafil-induced peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway.
Jain NK; Patil CS; Singh A; Kulkarni SK
Brain Res; 2001 Aug; 909(1-2):170-8. PubMed ID: 11478933
[TBL] [Abstract][Full Text] [Related]
27. In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach.
Gratzke C; Uckert S; Kedia G; Reich O; Schlenker B; Seitz M; Becker AJ; Stief CG
Urol Res; 2007 Feb; 35(1):49-54. PubMed ID: 17102958
[TBL] [Abstract][Full Text] [Related]
28. Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension.
Lewis GD; Semigran MJ
Curr Heart Fail Rep; 2004 Dec; 1(4):183-9. PubMed ID: 16036043
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.
Kloner RA
Circulation; 2004 Nov; 110(19):3149-55. PubMed ID: 15533876
[No Abstract] [Full Text] [Related]
30. Sildenafil reverses O2 constriction of the rabbit ductus arteriosus by inhibiting type 5 phosphodiesterase and activating BK(Ca) channels.
Thébaud B; Michelakis E; Wu XC; Harry G; Hashimoto K; Archer SL
Pediatr Res; 2002 Jul; 52(1):19-24. PubMed ID: 12084842
[TBL] [Abstract][Full Text] [Related]
31. T-0156, a novel phosphodiesterase type 5 inhibitor, and sildenafil have different pharmacological effects on penile tumescence and electroretinogram in dogs.
Mochida H; Noto T; Inoue H; Yano K; Kikkawa K
Eur J Pharmacol; 2004 Feb; 485(1-3):283-8. PubMed ID: 14757152
[TBL] [Abstract][Full Text] [Related]
32. Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity.
Zoraghi R; Corbin JD; Francis SH
J Biol Chem; 2006 Mar; 281(9):5553-8. PubMed ID: 16407275
[TBL] [Abstract][Full Text] [Related]
33. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal.
Atz AM; Wessel DL
Anesthesiology; 1999 Jul; 91(1):307-10. PubMed ID: 10422958
[No Abstract] [Full Text] [Related]
34. The discovery of novel, potent and selective PDE5 inhibitors.
Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
Bioorg Med Chem Lett; 2001 Sep; 11(18):2461-4. PubMed ID: 11549447
[TBL] [Abstract][Full Text] [Related]
35. Characterization of human, dog and rabbit corpus cavernosum type 5 phosphodiesterases.
Wang P; Wu P; Myers JG; Stamford A; Egan RW; Billah MM
Life Sci; 2001 Mar; 68(17):1977-87. PubMed ID: 11388700
[TBL] [Abstract][Full Text] [Related]
36. Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells.
Sarfati M; Mateo V; Baudet S; Rubio M; Fernandez C; Davi F; Binet JL; Delic J; Merle-Beral H
Blood; 2003 Jan; 101(1):265-9. PubMed ID: 12393651
[TBL] [Abstract][Full Text] [Related]
37. Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum.
Gopal VK; Francis SH; Corbin JD
Eur J Biochem; 2001 Jun; 268(11):3304-12. PubMed ID: 11389733
[TBL] [Abstract][Full Text] [Related]
38. Hypotensive interaction of sildenafil and nicorandil in rats through the cGMP pathway but not by K(ATP) channel activation.
Ishizuka N; Saito K; Akima M; Matsubara S; Saito M
Jpn J Pharmacol; 2000 Nov; 84(3):316-24. PubMed ID: 11138733
[TBL] [Abstract][Full Text] [Related]
39. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells.
Moreland RB; Goldstein I; Traish A
Life Sci; 1998; 62(20):PL 309-18. PubMed ID: 9600334
[TBL] [Abstract][Full Text] [Related]
40. Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor.
Mochida H; Takagi M; Inoue H; Noto T; Yano K; Fujishige K; Sasaki T; Yuasa K; Kotera J; Omori K; Kikkawa K
Eur J Pharmacol; 2002 Dec; 456(1-3):91-8. PubMed ID: 12450574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
